A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer
Journal of Gynecologic Oncology · 2024
DOI: 10.3802/jgo.2024.35.e76 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Hiromi Komazaki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Bevacizumab, Carboplatin, Paclitaxel, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society of Obstetrics and Gynecology.
Abstract (Originalsprache)
OBJECTIVE: This study compared the effectiveness, safety, and tolerability of dose-dense paclitaxel and carboplatin plus bevacizumab (ddTC+Bev) with ddTC for advanced ovarian cancer. METHODS: We retrospectively analyzed the clinical records of 134 patients who received ddTC+Bev or ddTC as first-line chemotherapy for stage III-IV ovarian cancer. Progression-free survival as primary endpoint of this study was compared using the log-rank test. Cox proportional hazards model and propensity score matching (PSM) were used to analyze prognostic factors, and the frequency of adverse events was examined using the χ² test. RESULTS: We categorized 134 patients in the ddTC+Bev (n=57) and ddTC (n=77) groups who started treatment at four related institutions from November 2013 to December 2017. No patients used poly (ADP-ribose) polymerase inhibitors as the first line maintenance therapy. The progression-free survival (PFS) of the ddTC+Bev group had a significantly better prognosis than that of the ddTC group (hazard ratio [HR]=0.50; 95% confidence interval [CI]=0.32-0.79; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Gynecology, National Center Cancer Hospital East, Kashiwa, Japan. htanabe@east.ncc.gp.jp.
- Department of Clinical Medicine (Biostatistics), School of Pharmacy, Kitasato University, Tokyo, Japan.
ORCID-Profile: Hiromi Komazaki, Kazuaki Takahashi, Hiroshi Tanabe, Yuichi Shoburu, Misato Kamii, Akina Tsuda, Motoaki Saito, Kyosuke Yamada, Hirokuni Takano, Hirofumi Michimae, Aikou Okamoto
Förderung
- Japan Society of Obstetrics and Gynecology
Zitieren
APA
Komazaki, H., Takahashi, K., Tanabe, H., Shoburu, Y., Kamii, M., Tsuda, A., Saito, M., Yamada, K., Takano, H., Michimae, H., & Okamoto, A. (2024). A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e76
Vancouver
Komazaki H, Takahashi K, Tanabe H, Shoburu Y, Kamii M, Tsuda A, et al. A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e76
BibTeX
@article{Komazaki2024,
author = {Komazaki, Hiromi and Takahashi, Kazuaki and Tanabe, Hiroshi and Shoburu, Yuichi and Kamii, Misato and Tsuda, Akina and Saito, Motoaki and Yamada, Kyosuke and Takano, Hirokuni and Michimae, Hirofumi and Okamoto, Aikou},
title = {A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer},
journal = {Journal of Gynecologic Oncology},
year = {2024},
doi = {10.3802/jgo.2024.35.e76}
}
EUVIMED